The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Open accessAbstract
Antibody drug conjugates (ADCs) employ the exquisite specificity of tumour-specific monoclonal antibodies (mAb) for the targeted delivery of highly potent cytotoxic drugs to the tumour site. The chemistry of the linker, which connects the drug to the mAb, determines how and when the drug is released from the mAb. This, as well as the chemistry of the drug, can dictate whether the drug can diffuse into surrounding cells, resulting in 'bystander killing'. Initially, any bystander killing mechanism of action of an ADC was understood to involve an essential sequence of steps beginning with surface antigen targeting, internalisation, intracellular linker cleavage, drug release, and diffusion of drug away from the targeted cell. However, recent studies indicate that, depending on the linker and drug combination, this mechanism may not be essential and ADCs can be cleaved extracellularly or via other mechanisms. In this minireview, we will examine the role of bystander killing by ADCs and explore the emerging evidence of how this can occur independently of internalisation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Antibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 525
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues
Buck, M. R., Karustis, D. G., Day, N. A., Honn, K. V., & Sloane, B. F. (1992) · Biochemical Journal · doi:10.1042/bj2820273 · Cited by 422
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 340
Reddy, V. Y., Zhang, Q. Y., & Weiss, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3849 · Cited by 318
Antibody Drug Conjugates for Cancer Therapy
Polakis, P. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009373 · Cited by 307
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 300
Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3787 · Cited by 299
Sutherland, M. S. K., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Golfier, S., Kopitz, C., Kahnert, A., Heisler, I., Schatz, C. A., Stelte-Ludwig, B., Mayer-Bartschmid, A., Unterschemmann, K., Bruder, S., Linden, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0926 · Cited by 249
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Campo, E., Muñoz, J., Miquel, R., Palacı́n, A., Cardesa, A., Sloane, B. F., & Emmert‐Buck, M. R. (1994) · PubMed Central · Cited by 214
Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., Han, T. H., Sievers, E. L., & Bartlett, N. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1425 · Cited by 213
Müller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., Lardinois, D., Heinzelmann-Schwarz, V. A., Schlaak, M., Kvasnicka, H.-M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0198 · Cited by 203
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber, H.-P., Sapra, P., Loganzo, F., & May, C. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.008 · Cited by 184
Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment
SLOANE, B., YAN, S., PODGORSKI, I., LINEBAUGH, B., CHER, M., MAI, J., CAVALLOMEDVED, D., SAMENI, M., DOSESCU, J., & MOIN, K. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.08.001 · Cited by 174
Dokter, W., Ubink, R., van der Lee, M., van der Vleuten, M., van Achterberg, T., Jacobs, D., Loosveld, E., van den Dobbelsteen, D., Egging, D., Mattaar, E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0040-t · Cited by 163
Rios‐Doria, J., Harper, J. W., Rothstein, R. P., Wetzel, L. K., Chesebrough, J. W., Marrero, A. M., Chen, C., Strout, P., Mulgrew, K. A., McGlinchey, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2854 · Cited by 150
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Singh, A. P., Sharma, S., & Shah, D. K. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9495-8 · Cited by 145
A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy
Bernardes, G. J. L., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J., & Neri, D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106527 · Cited by 133
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A. C., Masterson, L. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0233 · Cited by 124
Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., & Neri, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30569 · Cited by 124
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117
Govindan, S. V., Cardillo, T. M., Moon, S.-J., Hansen, H. J., & Goldenberg, D. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0586 · Cited by 111
A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Miller, M. L., Fishkin, N. E., Li, W., Whiteman, K. R., Kovtun, Y., Reid, E. E., Archer, K. E., Maloney, E. K., Audette, C. A., Mayo, M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0184 · Cited by 102
Smith, L. M., Nesterova, A., Alley, S. C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0026 · Cited by 101
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
McDonagh, C. F., Kim, K. M., Turcott, E., Brown, L. L., Westendorf, L., Feist, T., Sussman, D. R., Stone, I. J., Anderson, M. E., Miyamoto, J. B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0295 · Cited by 95
Ansell, S. M. (2014) · Blood · doi:10.1182/blood-2014-06-537514 · Cited by 93
Corso, A. D., Cazzamalli, S., Gébleux, R., Mattarella, M., & Neri, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00304 · Cited by 92
Li, F., Ulrich, M. L., Jonas, M., Stone, I. J., Linares, G., Zhang, X., Westendorf, L., Benjamin, D. R., & Law, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0019 · Cited by 91
Cazzamalli, S., Corso, A. D., & Neri, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.023 · Cited by 88
Oflazoglu, E., Stone, I. J., Brown, L. L., Gordon, K. A., van Rooijen, N., Jonas, M., Law, C.-L., Grewal, I. S., & Gerber, H.-P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604812 · Cited by 81
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L. B., Kunz, A., Boghaert, E. R., Hamann, P. R., & Damle, N. K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0260-5 · Cited by 64
Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O’Connor, O. A., Sharman, J. P., Feldman, T. A., Savage, K. J. J., Shustov, A. R., Diefenbach, C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1256481 · Cited by 64
Gébleux, R., Wulhfard, S., Casi, G., & Neri, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0480 · Cited by 61
Cazzamalli, S., Corso, A. D., & Neri, D. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0283 · Cited by 60
Perez, E. A., Hurvitz, S. A., Amler, L. C., Mundt, K., Ng, V., Guardino, E., & Gianni, L. (2014) · Breast Cancer Research · doi:10.1186/bcr3661 · Cited by 58
Bartlett, N. L., Sharman, J. P., Oki, Y., et al. (2013) · Blood · doi:10.1182/blood.v122.21.848.848 · Cited by 49
Martino, B., le Coutre, P., Grießhammer, M., Illmer, T., Schlag, R., Waller, C. F., Liberati, A. M., Schafhausen, P., Daher, R. T., Vannucchi, A. M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3197.3197 · Cited by 32
Steiner, M., Hartmann, I., Perrino, E., Casi, G., Samatanga, B., Jelesarov, I., Bernardes, G. J. L., & Neri, D. (2012) · Chemical Science · doi:10.1039/c2sc21107f · Cited by 32
Pro, B., Advani, R. H., Brice, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.1809.1809 · Cited by 29
Yasenchak, C. A., Farber, C. M., Budde, L. E., Ansell, S. M., Advani, R. H., Holkova, B., Halwani, A. S., Knapp, M. H., Fayad, L., Kolibaba, K. S., et al. (2014) · Blood · doi:10.1182/blood.v124.21.1745.1745 · Cited by 17
CD30-targeting immunoconjugates and bystander effects
Masuda, S., Miyagawa, S., Sougawa, N., & Sawa, Y. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.159-c1 · Cited by 15
Brown, M. P., & Staudacher, A. H. (2014) · Immunotherapy · doi:10.2217/imt.14.13 · Cited by 15
Self-citation
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Metadata
- Authors
- Staudacher, A. H., & Brown, M. P.
- Venue
- British Journal of Cancer
- Published
- 2017-10-24
- Volume
- 117
- Issue
- 12
- Pages
- 1736-1742
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2767025650
- Cited by
- 540
- References
- 61
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.